Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Your RPS

RPS backs changes to interval between COVID-19 vaccination doses

The Royal Pharmaceutical Society says that the government’s updated vaccination strategy “will protect a greater number of people from COVID-19 disease”.


A booster dose is essential for long-term protection from COVID-19, but it can be administered up to 12 weeks after the initial dose

The Royal Pharmaceutical Society (RPS) has said it strongly supports changes to the planned interval between currently licensed COVID-19 vaccine doses in the UK.

The government has said that the second dose of both licensed vaccines “should be routinely scheduled between four and 12 weeks after the first dose”, rather than the previous recommendation of a three- to four-week gap. 

In a statement published on 6 January 2020, the RPS said that the updated strategy “will protect a greater number of people from COVID-19 disease”. It noted that clinical trial data shows “substantial protection from developing COVID-19 is given from the first dose of the vaccine”, and added that a booster dose is essential for long-term protection, “but this booster dose can be given later to enable more of the population to receive the initial dose quickly”.

The Society said its decision was informed by a range of sources, including a statement from the Joint Committee on Vaccination and Immunisation which, among other points, advised a maximum interval between the first and second doses of 12 weeks.

The Society also noted clinical trial data and regulatory approval for the Oxford/AstraZeneca vaccine, regulatory approval for the Pfizer/BioNTech vaccine and a statement from the British Society for Immunology, which said that delaying a booster dose of a protein antigen vaccine by eight weeks would be unlikely to have a negative effect on the overall immune response post-booster.

The RPS also referenced a joint letter from the UK chief medical officers, dated 31 December 2020, which said that “in terms of protecting priority groups, a model where we can vaccinate twice the number of people in the next 2–3 months is obviously much more preferable in public health terms than one where we vaccinate half the number but with only slightly greater protection”.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2021.20208718

Readers' comments (1)

  • Delaying the second dose has possible implications for the extent of the immune response in elderly patients.
    Is there evidence that it will provide sufficient protection until after the second dose?
    I believe the Swiss authorities have decided to maintain the original dosage regimen.
    Alan Paul

    Unsuitable or offensive? Report this comment

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

PJJ Static MPU
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.